Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Satellos Bioscience Inc T.MSCL

Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and... see more

Recent & Breaking News (TSX:MSCL)

Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Business Wire April 8, 2024

Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights

Business Wire March 27, 2024

Satellos to Present at Upcoming Virtual Investor Conferences in March and April

Business Wire March 14, 2024

Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024

Business Wire March 5, 2024

Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference

Business Wire March 4, 2024

Satellos Recognized as a Top 50 TSX Venture Exchange Company

Business Wire February 21, 2024

Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Business Wire February 20, 2024

Satellos to Commence Trading on the Toronto Stock Exchange

Business Wire February 14, 2024

24/02/13 - TSX Venture Exchange Stock Maintenance Bulletins

Canada NewsWire February 14, 2024

Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy

Business Wire February 13, 2024

Satellos Announces Management Team Update

Business Wire January 23, 2024

Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Business Wire January 16, 2024

Satellos Bioscience Announces 2023 Q3 Financial Results and Operational Highlights

Business Wire November 22, 2023

Satellos to Present at the Piper Sandler 35th Annual Healthcare Conference

Business Wire November 20, 2023

Satellos Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program

Business Wire November 14, 2023

Satellos to Present at the Stifel 2023 Healthcare Conference

Business Wire November 2, 2023

Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023

Newsfile September 20, 2023

Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services

Newsfile September 7, 2023

Satellos Expands Leadership Team with New CFO Appointment

Newsfile September 5, 2023

Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights

Newsfile August 29, 2023